Clinical trials of vascular brachytherapy for in-stent restenosis: update.
Vascular brachytherapy has become the therapeutic strategy of choice for in-stent restenosis. Clinical trials evaluating the effectiveness and safety of this technology have enrolled nearly 4000 patients using both gamma and beta emitters. At present, ongoing controversies include optimal dosimetry, whether beta emitters are as effective as gamma and whether centering delivery systems perform better than non-centering systems. Complications of brachytherapy such as edge effect, late thrombosis and late restenosis have received increasing attention. This review provides an update of the current status of clinical trials utilizing vascular brachytherapy to prevent the recurrence of in-stent restenosis.
Ajani
A E
AE
Experimental Angioplasty and Vascular Brachytherapy, Cardiovascular Research Institute, 110 Irving Street, Northwest, Suite 4B-1, Washington, DC 20010, USA.
Kim
H S
HS
Waksman
R
R
D015906:Angioplasty, Balloon, Coronary; D001610:Beta Particles; D001918:Brachytherapy; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000532:radiotherapy*; D005352:Fibromuscular Dysplasia / Q000532:radiotherapy*; D005720:Gamma Rays; D006083:Graft Occlusion, Vascular / Q000532:radiotherapy*; D006801:Humans; D012008:Recurrence; D015607:Stents; D016896:Treatment Outcome